Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Open accessThe DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.
Abstract
Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation. Recent data from normal subjects has shown that normal mPAP was 14.0±3.3 mmHg. Two standard deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile). This definition is no longer arbitrary, but based on a scientific approach. However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure. Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH associated with mPAP >20 mmHg. Prospective trials are required to determine whether this PH population might benefit from specific management. Regarding clinical classification, the main Task Force changes were the inclusion in group 1 of a subgroup “pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers”, due to the specific prognostic and management of these patients, and a subgroup “PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement”, due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 The slope of the mean pulmonary arterial pressure (mPAP)–cardiac output (CO) relationship is different in normal control versus pulmonary arterial hypertension (PAH) subjects. Reproduced and modified from [26] with permission.](https://figures.cochat.ai/paper-figures/36e057af8c4544adb1c352faf9a06761/haemodynamic-definitions-and-updated-clinical-classification-of-pulmonary-figure-1.jpg)
![FIGURE 2 Knowledge of the mean pulmonary arterial pressure (mPAP)–cardiac output (CO) relationship does not allow distinction between left heart disease (LHD) and pulmonary vascular disease (PVD) patients; knowledge of exercise pulmonary arterial wedge pressure is also required. TPR: total pulmonary resistance; WU: Wood Units. Reproduced from [29] with permission.](https://figures.cochat.ai/paper-figures/8474dfd09d604465902cbdde1d1fd85a/haemodynamic-definitions-and-updated-clinical-classification-of-pulmonary-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pulmonary hypertension can also occur in the context of congenital heart disease.(301)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [301]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [62]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationDe Rosa, S., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,007
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationUpdated Clinical Classification of Pulmonary Hypertension
Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z.-C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.012 · Cited by 2,093
Self-citationClinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Self-citationDefinitions and Diagnosis of Pulmonary Hypertension
Hoeper, M. M., Bogaard, H. J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T., Torres, F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.032 · Cited by 1,766
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Self-citation
Research works printed but not linked: 2
- Reeves J , Dempsey J , Grover R . Pulmonary circulation during exercise. In: Weir EK , Reeves JT , eds. Pulmonary Vascular Physiology and Physiopathology. New York, Marcel Dekker, 1989; pp. 107–133. · doi:10.1201/9781003573739-5
- Tamura Y , Furukawa A , Li T , et al. Severe pulmonary arterial hypertension in patients treated by Chinese herb nature indigo: Qing-Dai. Poster presentation at the 6th World Symposium on Pulmonary Hypertension, Nice, 2018; A108.
Cited by
Items 701–800 of 1,004
Parker, M. J. S., Jee, A. S., Hansen, D., Proudman, S., Youssef, P. P., Kenna, T., Stevens, W., Nikpour, M., Sahhar, J., & Corte, T. J. (2024) · Rheumatology · doi:10.1093/rheumatology/keae110 · Cited by 26
Mondéjar‐Parreño, G., Pérez‐Vizcaíno, F., & Cogolludo, A. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00634 · Cited by 26
An update on sarcoidosis-associated pulmonary hypertension
Bandyopadhyay, D., & Humbert, M. J. C. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000701 · Cited by 26
Purinergic Dysfunction in Pulmonary Arterial Hypertension
Cai, Z., Tu, L., Guignabert, C., Merkus, D., & Zhou, Z. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017404 · Cited by 26
Hoeper, M. M., Sanchez, M.-A. G., Humbert, M. J. C., Pittrow, D., Simonneau, G., Gall, H. J., Grünig, E., Klose, H. F. E., Halank, M., Langleben, D., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106241 · Cited by 26
Self-citationKim, N. H., Hemnes, A. R., Chakinala, M. M., Highland, K. B., Chin, K., McLaughlin, V. V., Zhao, C., NARAYAN, V., & Farber, H. W. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.01.006 · Cited by 26
Shao, Y., Yin, X., Qin, T., Zhang, R., Zhang, Y., & Wen, X. (2021) · BioMed Research International · doi:10.1155/2021/5595614 · Cited by 26
Hautbergue, T., Antigny, F., Boët, A., Haddad, F., Masson, B., Lambert, M., Delaporte, A., Ménager, J.-B., Savale, L., Pavec, J. L., et al. (2021) · Cells · doi:10.3390/cells10061559 · Cited by 26
The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease
Huang, X. J., Zeng, Z., Li, S., Xie, Y., & Tong, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122760 · Cited by 26
Nestin-Expressing Cells in the Lung: The Bad and the Good Parts
Jaramillo-Rangel, G., Chávez-Briones, M.-D.-L., Ancer-Arellano, A., & Ortega-Martínez, M. (2021) · Cells · doi:10.3390/cells10123413 · Cited by 25
Echocardiographic Screening Methods for Pulmonary Hypertension: A Practical Review
Jang, A. Y., & Shin, M.-S. (2019) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2019.0104 · Cited by 25
Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension
Al‐Qadi, M. O., LeVarge, B. L., & Ford, H. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.616720 · Cited by 25
Valentin, S., Maurac, A., Sitbon, O., Beurnier, A., Gomez, E., Guillaumot, A., Textoris, L., Fay, R., Savale, L., Jaïs, X., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04066-2020 · Cited by 25
Self-citationDuncan, M. S., Alcorn, C., Freiberg, M. S., So‐Armah, K., Patterson, O. V., DuVall, S. L., Crothers, K. A., Re, V. L., Butt, A. A., Lim, J. K., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00116-1 · Cited by 25
Schistosome-Associated Pulmonary Arterial Hypertension: A Review Emphasizing Pathogenesis
Ferrari, T. C. A., Albricker, A. C. L., Gonçalves, I. M., & Freire, C. M. V. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.724254 · Cited by 25
Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants
Min, J., Appleby, D. H., McClelland, R. L., Minhas, J., Holmes, J. H., Urbanowicz, R. J., Pugliese, S. C., Mazurek, J. A., Smith, K. A., Fritz, J. S., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202110-1139oc · Cited by 25
Kozitza, C. J., Dharmavaram, N. L., Tao, R., Tabima, D. M., Chesler, N. C., & Raza, F. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12029 · Cited by 25
Pennec, R. L., Tromeur, C., Orione, C., Robin, P., Mao, R. L., MOREUIL, C. D., Jevnikar, M., Hoffman, C., Savale, L., Couturaud, F., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.851935 · Cited by 25
Self-citationAlves-Silva, J. M., Zuzarte, M., Marques, C., Viana, S., Preguiça, I., Baptista, R., Ferreira, C., Cavaleiro, C., Domingues, N. S., Sardão, V. A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2022.106151 · Cited by 25
Shi, B., Zhou, T., Lv, S., Wang, M., Chen, S., Heidari, A. A., Huang, X., Chen, H., Wang, L., & Wu, P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105529 · Cited by 25
Mesenchymal Stem Cell–derived Nanovesicles as a Credible Agent for Therapy of Pulmonary Hypertension
Hu, L., Wang, J., Lin, D., Shen, Y., Huang, H., Cao, Y. Z., Li, Y., Li, K., Yu, Y., Yu, Y., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0415oc · Cited by 25
Pizzicato, L. N., Nadipelli, V. R., Governor, S., Mao, J., Lanes, S., Butler, J., Pepe, R. S., Phatak, H. M., & El‐Kersh, K. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12090 · Cited by 25
Skeletal muscle blood flow during exercise is reduced in a rat model of pulmonary hypertension
Long, G., Troutman, A. D., Gray, D. A., Fisher, A. J., Lahm, T., Coggan, A. R., & Brown, M. B. (2022) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00327.2021 · Cited by 25
Leiva, O., Ren, S., Neuberg, D. S., Bhatt, A. S., Jenkins, A., Rosovsky, R. P. G., Leaf, R. K., Goodarzi, K., & Hobbs, G. S. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03454-1 · Cited by 25
The Cardiopulmonary Complications of Sickle Cell Disease
Desai, A. A., Machado, R. F., & Cohen, R. T. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.014 · Cited by 25
Mavrogeni, S. I., Kallifatidis, A., Kourtidou, S., Lama, N., Christidi, A., Detorakis, Ε. T., Chatzantonis, G., Vrachliotis, T. G., Karamitsos, T. D., Κούσκουρας, Κ., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.01.003 · Cited by 25
MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment
Wołowiec, Ł., Mędlewska, M., Osiak, J., Wołowiec, A., Grześk, E., Jaśniak, A., & Grześk, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119735 · Cited by 25
Willer, A. S., Gomes, J., Adão, R., Brás‐Silva, C., Eyries, M., Pérez‐Vizcaíno, F., Capuano, V., Montani, D., & Antigny, F. (2023) · The Journal of Physiology · doi:10.1113/jp284936 · Cited by 25
Self-citationRecent Advances in Pediatric Pulmonary Hypertension: Implications for Diagnosis and Treatment
Sullivan, R. T., Raj, J. U., & Austin, E. D. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.001 · Cited by 25
Frequency and implications of malnutrition in systemic sclerosis
Fairley, J. L., Hansen, D., Quinlivan, A., Proudman, S., Sahhar, J., Ngian, G., Walker, J. G., Host, L., Morrisroe, K., Stevens, W., et al. (2024) · Rheumatology · doi:10.1093/rheumatology/keae209 · Cited by 25
Abdulaal, L., Maiter, A., Salehi, M., Sharkey, M. J., Alnasser, T. N., Garg, P., Rajaram, S., Hill, C., Johns, C., Rothman, A. M. K., et al. (2024) · Frontiers in Radiology · doi:10.3389/fradi.2024.1335349 · Cited by 25
Bioinformatics analysis of hypoxia associated genes and inflammatory cytokine profiling in COPD-PH
Choudhury, P., Dasgupta, S., Kar, A., Sarkar, S., Chakraborty, P., Bhattacharyya, P., Roychowdhury, S., & Chaudhury, K. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107658 · Cited by 25
Salazar, I. M. C., Lancaster, A. C., Jani, V., Montovano, M. J., Kauffman, M., Weller, A., Ambale‐Venkatesh, B., Zimmerman, S. L., Simpson, C. E., Kolb, T. M., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00420-2024 · Cited by 25
Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension
Berghausen, E. M., Gnatzy-Feik, L., Zierden, M., Vantler, M., & Rosenkranz, S. (2019) · Herz · doi:10.1007/s00059-019-4795-6 · Cited by 25
Wang, Y., Duo, D., Yan, Y., He, R., Wang, S., Wang, A., & Wu, X. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00775 · Cited by 25
Ruigrok, D., Meijboom, L. J., Nossent, E. J., Boonstra, A., Braams, N. J., van Wezenbeek, J., de Man, F. S., Marcus, J. T., Noordegraaf, A. V., Symersky, P., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00109-2020 · Cited by 25
Sodium Tanshinone II Sulfonate A Ameliorates Hypoxia-Induced Pulmonary Hypertension
Bao, Y.-R., Chen, J., Jiang, Y., Wang, L., Xue, R., Qian, J.-X., & Zhang, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00687 · Cited by 25
Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension
Lahm, T., Hess, E., Barón, A. E., Maddox, T. M., Plomondon, M. E., Choudhary, G., Maron, B. A., Zamanian, R. T., & Leary, P. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.258 · Cited by 25
Gillmeyer, K. R., Núñez, E., Rinne, S. T., Qian, S. X., Klings, E. S., & Wiener, R. S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.12.010 · Cited by 25
Burden of pulmonary arterial hypertension in England: retrospective HES database analysis
Exposto, F., Hermans, R., Nordgren, Ã., Taylor, L., Rehman, S. S., Ogley, R., Davies, E. W., Yesufu-Udechuku, A., & Beaudet, A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466621995040 · Cited by 25
Acute exacerbation in interstitial lung disease
Alhamad, E., Cal, J. G., Alrajhi, N. N., & AlBoukai, A. (2021) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_14_21 · Cited by 25
A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension
Lammers, A. E., Apitz, C., Michel‐Behnke, I., & Köestenberger, M. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-119 · Cited by 25
Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature
Yoo, H. H. B., & Marin, F. L. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s295463 · Cited by 25
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Self-citationThe Physiology of Interstitial Lung Disease
Troy, L. K., & Corte, T. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11359-5 · Cited by 25
Post-tuberculosis pulmonary hypertension: a case of global disparity in health care
Walsh, K. F., & Lui, J. K. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00042-0 · Cited by 25
Artificial intelligence-based echocardiography assessment to detect pulmonary hypertension
Salehi, M., Alabed, S., Sharkey, M. J., Maiter, A., Dwivedi, K., Yardibi, T., Selej, M., Hameed, A. G., Charalampopoulos, A. F., Kiely, D. G., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00592-2024 · Cited by 24
Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies
Adu‐Amankwaah, J., You, Q., Liu, X., Jiang, J., Yang, D., Liu, K., Yuan, J., Wang, Y., Hu, Q., & Tan, R. (2025) · MedComm · doi:10.1002/mco2.70134 · Cited by 24
Schneider, M., Ran, H., Pistritto, A. M., Gerges, C., Heidari, H., Nitsche, C., Gerges, M., Hengstenberg, C., Mascherbauer, J., Binder, T. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235716 · Cited by 24
Extracellular Vesicles as Unique Signaling Messengers: Role in Lung Diseases
Gao, Y., & Raj, J. U. (2020) · Comprehensive physiology · doi:10.1002/cphy.c200006 · Cited by 24
Dong, M. L., Lan, I. S., Yang, W., Rabinovitch, M., Feinstein, J. A., & Marsden, A. L. (2021) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-021-01519-4 · Cited by 24
Saleh, D., Fisher, J. H., Provencher, S., Liang, Z., Ryerson, C. J., & Weatherald, J. C. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-325oc · Cited by 24
Predictors of survival in portopulmonary hypertension: a 20-year experience
Aggarwal, M., Li, M., Bhardwaj, A., Wallace, W. D., Wang, X., Carey, W. D., Dweik, R. A., Heresi, G. A., & Tonelli, A. R. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002322 · Cited by 24
Sahay, S., Bhatt, J., Beshay, S. M., Guha, A., Nguyen, D. T., Graviss, E. A., & Nagueh, S. F. (2021) · Pulmonary Circulation · doi:10.1002/pul2.12026 · Cited by 24
Certain, M. C., Baron, A., Turpin, M., Ebstein, N., Boucly, A., Beurnier, A., Jevnikar, M., Roche, A., Keddache, S., Bulifon, S., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00107-2022 · Cited by 24
Self-citationMajeed, R. W., Wilkins, M. R., Howard, L., Hassoun, P. M., Anthi, A., Cajigas, H. R., Cannon, J. E., Chan, S. Y., Damonte, V., Elwing, J., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12123 · Cited by 24
Liu, Y., Tang, B., Lü, M., & Wang, H. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17681 · Cited by 24
Hungerford, S. L., Kearney, K. L., Song, N., Bart, N., Kotlyar, E., Lau, E., Jabbour, A., Hayward, C., Muller, D. W. M., & Adji, A. I. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14180 · Cited by 24
Aktaa, S., Gale, C. P., Brida, M., Giannakoulas, G. A., Kovács, G., Adir, Y., Benza, R. L., Böhm, M., Coats, A. J. S., D’Alto, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2830 · Cited by 24
Grynblat, J., Malekzadeh-Milani, S. G., Méot, M., Perros, F., Szézépanski, I., Morisset, S., Ovaert, C., Bonnet, C., Maragnès, P., Ranchoup, J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029085 · Cited by 24
Self-citationMiranda, W. R., Jain, C. C., Borlaug, B. A., Connolly, H. M., Burchill, L. J., Bruaene, A. V. D., & Egbe, A. C. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3119 · Cited by 24
Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension
Balasubramanian, A., Larive, A. B., Horn, E. M., DuBrock, H. M., Mehra, R., Jacob, M. S., Hemnes, A. R., Leopold, J. A., Radeva, M., Hill, N. S., et al. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.02.009 · Cited by 24
IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension
Gillies, H., Chakinala, M. M., Dake, B. T., Feldman, J. P., Hoeper, M. M., Humbert, M. J. C., Jing, Z., Langley, J., McLaughlin, V. V., Niven, R. W., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12352 · Cited by 24
Cavarretta, E., D’Ascenzi, F., Bianco, M., Castelletti, S., Cavigli, L., Cecchi, F., D’Andrea, A., Luca, A. D., Salvo, G. D., Nistri, S., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132230 · Cited by 24
Pulmonary Hypertension Associated with Connective Tissue Disease
Mathai, S. C. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.08.003 · Cited by 24
Mean platelet volume as a predictor of pulmonary hypertension in patients with stable COPD
Fathy, M., Ali, A. M. M., Abbas, A. M., Awad, M. S., Gouda, M., & Sediq, A. (2019) · International Journal of COPD · doi:10.2147/copd.s176413 · Cited by 24
Dobler, C. L., Krüger, B., Strahler, J., Weyh, C., Gebhardt, K., Tello, K., Ghofrani, H. A., Sommer, N., Gall, H. J., Richter, M. J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124023 · Cited by 24
Association of premature menopause with incident pulmonary hypertension: A cohort study
Honigberg, M. C., Patel, A. P., Lahm, T., Wood, M. J., Ho, J. E., Kohli, P., & Natarajan, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247398 · Cited by 24
Clinical Phenogroups in Heart Failure with Preserved Ejection Fraction
Sorimachi, H., Omote, K., & Borlaug, B. A. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.009 · Cited by 24
SUR1 As a New Therapeutic Target for Pulmonary Arterial Hypertension
Ribeuz, H. L., Masson, B., Capuano, V., Dutheil, M., Gooroochurn, H., Boët, A., Ghigna, M., de Montpréville, V., Girerd, B., Lambert, M., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0180oc · Cited by 24
Self-citationKallonen, J., Korsholm, K., Bredin, F., Corbascio, M., Andersen, M. J., Ilkjær, L. B., Mellemkjær, S., & Sartipy, U. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12093 · Cited by 24
Liu, Z., Mo, L., Cao, W., Wang, K., Gong, H., Li, C., Pan, W., & He, J. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1516365 · Cited by 23
Yogeswaran, A., Hassoun, P. M., Saleh, K., Fünderich, M., Balasubramanian, A., Konswa, Z., Kiely, D. G., Lawrie, A., Thenappan, T., Eichstaedt, C. A., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202412-2371oc · Cited by 23
Lee, S. A., Tanade, C., Zhou, H., Lee, J., Thukral, M., Han, M., Choi, R., Khan, M. S. H., Lu, B., Gwak, M., et al. (2025) · International Conference on Learning Representations · doi:10.48550/arxiv.2510.25785 · Cited by 23
van Dongen, C., Janssen, M. T. H. F., van der Horst, R. P. J., Kraaij, D. J. W. V., Peeters, R., van den Toorn, L., & Mostard, R. L. M. (2020) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2020_001784 · Cited by 23
Oakland, H. T., Joseph, P., Elassal, A., Cullinan, M., Heerdt, P. M., & Singh, I. (2020) · Pulmonary Circulation · doi:10.1177/2045894020972273 · Cited by 23
Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension
Dara, A., Arvanitaki, A., Theodorakopoulou, M. P., Athanasiou, C., Pagkopoulou, E., & Boutou, A. (2021) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.32.1.6 · Cited by 23
Richter, M. J., Zedler, D., Berliner, D., Douschan, P., Gall, H. J., Ghofrani, H. A., Kimmig, L. M., Kremer, N., Olsson, K. M., da Rocha, B. R. B., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.775039 · Cited by 23
Agnihotri, V. V., Agrawal, Y. O., Goyal, S. N., Sharma, C., & Ojha, S. K. (2022) · Molecules · doi:10.3390/molecules27113490 · Cited by 23
Rodríguez‐Espinosa, D., Guzmán-Bofarull, J., Fuente-Mancera, J. C. D. L., Maduell, F., Broseta, J. J., & Farrero, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.913580 · Cited by 23
Ismat, F. A., Usansky, H. H., Villa, R., Zou, J., & Teper, A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02296-x · Cited by 23
2022 Brazilian Thoracic Association recommendations for long-term home oxygen therapy
Castellano, M. V. C. D. O., Pereira, L. F. F., Feitosa, P. H. R., Knorst, M. M., Salim, C., Rodrigues, M. M., Ferreira, E. V. M., Duarte, R., Togeiro, S. M., Stanzani, L. Z. L., et al. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20220179 · Cited by 23
Decreased circulating microRNA-21 and microRNA-143 are associated to pulmonary hypertension
Düzgün, Z., KAYIKÇIOĞLU, L. M., Aktan, Ç., Bara, B., Eroglu, F. Z., Yağmur, B., Çetintaş, V. B., BAYINDIR, M., Nalbantgil, S., & Vardarli, A. T. (2023) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5566 · Cited by 23
Exercise Testing in the Risk Assessment of Pulmonary Hypertension
Forbes, L. M., Bull, T., Lahm, T., Make, B. J., & Cornwell, W. K. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.04.013 · Cited by 23
Braams, N. J., Kianzad, A., van Wezenbeek, J., Wessels, J. N., Jansen, S. M. A., Andersen, S., Boonstra, A., Nossent, E. J., Marcus, J. T., Bayoumy, A. A., et al. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.010336 · Cited by 23
Grynblat, J., Khouri, C., Hlavaty, A., Jaïs, X., Savale, L., Chaumais, M., Kularatne, M., Jevnikar, M., Boucly, A., Antigny, F., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.02158-2023 · Cited by 23
Self-citationNovel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension
Wu, D., Vuuren, R. D. J., Dasgupta, A., Al‐Qazazi, R., Chen, K., Martin, A. Y., Mewburn, J. D., Alizadeh, E., Lima, P., Jones, O., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22822 · Cited by 23
Mukherjee, M., Mathai, S. C., Jellis, C. L., Freed, B. H., Yanek, L. R., Agoglia, H. K., Chiu, C., Jani, V., Simpson, C. E., Brittain, E. L., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017074 · Cited by 23
Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension
Jalce, G., & Guignabert, C. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00234.2019 · Cited by 23
Zou, R. H., Wallace, W. D., Nouraie, M. S., Chan, S. Y., & Risbano, M. G. (2019) · Pulmonary Circulation · doi:10.1177/2045894019891912 · Cited by 23
Pulmonary arterial hypertension: the case for a bioelectronic treatment
Ntiloudi, D., Qanud, K., Tomaio, J. N., Giannakoulas, G. A., Al‐Abed, Y., & Zanos, S. P. (2019) · Bioelectronic Medicine · doi:10.1186/s42234-019-0036-9 · Cited by 23
McDowell, R. E., Aulak, K. S., Almoushref, A., Melillo, C. A., Brauer, B. E., Newman, J. E., Tonelli, A. R., & Dweik, R. A. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00389.2019 · Cited by 23
Heiden, G. I., Sobral, J. B., Freitas, C. S. G., de Albuquerque, A. L. P., Salge, J. M., Kairalla, R. A., Fernandes, C. J. C. D. S., de Carvalho, C. R. R., Souza, R., & Baldi, B. G. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.05.609 · Cited by 23
Self-citationSarcoidosis-Associated Pulmonary Hypertension
Huitema, M. P., Mathijssen, H., Mager, J. J., Snijder, R. J., Grutters, J. C., & Post, M. C. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1713615 · Cited by 23
Dynamic right ventricular function response to incremental exercise in pulmonary hypertension
Singh, I., Oliveira, R. K. F., Heerdt, P. M., Brown, M. B., Faria‐Urbina, M., Waxman, A. B., & Systrom, D. M. (2020) · Pulmonary Circulation · doi:10.1177/2045894020950187 · Cited by 23
Gelinas, S., Benson, C. E., Khan, M. A., Berger, R. M. F., Trembath, R. C., Machado, R. D., & Southgate, L. (2020) · Genes · doi:10.3390/genes11111328 · Cited by 23
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis
Bruni, C., Guignabert, C., Manetti, M., Matucci‐Cerinic, M., & Humbert, M. J. C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30356-8 · Cited by 23
Association between Leflunomide and Pulmonary Hypertension
Lacoste-Palasset, T., Chaumais, M., Weatherald, J. C., Savale, L., Jaïs, X., Price, L. C., Khouri, C., Bulifon, S., Seferian, A., Jevnikar, M., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-913oc · Cited by 23
Self-citationDinarti, L. K., Anggrahini, D. W., Lilyasari, O., Siswanto, B. B., & Hartopo, A. B. (2021) · Global Heart · doi:10.5334/gh.944 · Cited by 23
Bai, Z., Xu, L., Dai, Y., Yuan, Q., & Zhou, Z. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3069 · Cited by 23
Metadata
- Authors
- Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R.
- Affiliations
- Université Paris-Sud (FR)
- The University of Sydney (AU)
- The Royal Free Hospital (GB)
- Mayo Clinic (US)
- Milpark Hospital (ZA)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801913
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351336
- OpenAlex
- W2904180601
- Cited by
- 3,813
- References
- 87
- Citations by year
- 2026: 208 · 2025: 356 · 2024: 480 · 2023: 541 · 2022: 716 · 2021: 711 · 2020: 558 · 2019: 225
- FWCI
- 282.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0033)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Keywords
- pulmonary hypertension, clinical classification, precapillary pulmonary hypertension, pulmonary arterial hypertension, pulmonary vascular resistance, mean pulmonary artery pressure, pulmonary vascular disease, pulmonary veno-occlusive disease, calcium channel blockers, right heart catheterization, reference values
- MeSH terms
- Consensus Statements as Topic, Heart Diseases, Hemodynamics, Humans, Hypertension, Pulmonary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.